XNASJANX
Market cap2.70bUSD
Jan 10, Last price
46.76USD
1D
-7.99%
1Q
-5.63%
IPO
131.94%
Name
Janux Therapeutics Inc
Chart & Performance
P/E
—
P/S
334.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
8m
-6.14%
Net income
-58m
L+7.64%
CFO
-51m
L+17.83%
Earnings
Jun 26, 2025
Profile
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 8,083 -6.14% | 8,612 136.79% | |||
Cost of revenue | 83,017 | 76,544 | |||
Unusual Expense (Income) | |||||
NOPBT | (74,934) | (67,932) | |||
NOPBT Margin | |||||
Operating Taxes | (8,905) | ||||
Tax Rate | |||||
NOPAT | (74,934) | (59,027) | |||
Net income | (58,293) 7.64% | (54,154) 66.33% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 56,530 | 500 | |||
BB yield | -11.97% | -0.09% | |||
| Debt | |||||
Debt current | 3,034 | 763 | |||
Long-term debt | 47,567 | 49,847 | |||
Deferred revenue | 2,221 | ||||
Other long-term liabilities | 2,221 | ||||
Net debt | (293,427) | (277,222) | |||
| Cash flow | |||||
Cash from operating activities | (50,575) | (42,922) | |||
CAPEX | (1,850) | (6,445) | |||
Cash from investing activities | (41,194) | 58,266 | |||
Cash from financing activities | 59,548 | 500 | |||
FCF | (73,410) | (86,795) | |||
| Balance | |||||
Cash | 344,028 | 327,016 | |||
Long term investments | 816 | ||||
Excess cash | 343,624 | 327,401 | |||
Stockholders' equity | (168,052) | (111,963) | |||
Invested Capital | 538,460 | 462,450 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 44,016 | 41,470 | |||
Price | 10.73 -18.53% | 13.17 -33.25% | |||
Market cap | 472,295 -13.52% | 546,155 -32.88% | |||
EV | 178,868 | 268,933 | |||
EBITDA | (72,979) | (67,091) | |||
EV/EBITDA | |||||
Interest | 4,032 | ||||
Interest/NOPBT | |||||